Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Sarcoma, Kaposi 1Myelodysplastic Syndromes 1Lymphoma 1Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Maraviroc × Clear all
NCT01276236 2021-03-05

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

University of California, San Francisco

Phase 2 Completed
13 enrolled 16 charts
Sarcoma

Sarcoma, Kaposi

NCT01785810 2021-01-11

Phase II Maraviroc for GVHD Prevention

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
37 enrolled 17 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT02799888 2016-06-15

Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

Affiliated Hospital to Academy of Military Medical Sciences

Phase 2 Unknown
40 enrolled
LymphoidMyeloid

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡